PSMD1 and COVID-19: Serum samples from pre-COVID-19 controls (n = 7), from healthy people collected in the first week of June 2020 (COVID-19 HVC, n = 50), and from convalescent patients (n = 50) were evaluated for antibodies (pan-Ig) directed against NP, RBD and S1 in the COVID-19 Multiplex Assay.